Clinical Trials Logo

Neuroendocrine Tumor Grade 2 clinical trials

View clinical trials related to Neuroendocrine Tumor Grade 2.

Filter by:
  • None
  • Page 1

NCT ID: NCT06395402 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

LUMOD-ID
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will: - Undergo Somatostatin Receptor (SSTR) positron emission tomography (PET) imaging, such as a DOTATOC PET/CT scan - Be randomized to receive standard treatment (as per FDA guidelines) or investigational treatment (customized dosing of Lutathera based upon dosimetry) - Undergo blood tests for 4 to 8 weeks after each Lutathera treatment - Complete patient reported outcome questionnaires - Visit the clinic for follow-up about every 8 weeks.

NCT ID: NCT06148636 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Start date: November 10, 2023
Phase: Early Phase 1
Study type: Interventional

This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.

NCT ID: NCT05111509 Enrolling by invitation - Clinical trials for Neuroendocrine Tumor Grade 2

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Start date: August 22, 2022
Phase: Early Phase 1
Study type: Interventional

This is a first in man study to determine if [203Pb]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy in neuroendocrine therapy.

NCT ID: NCT04789109 Recruiting - Liver Metastases Clinical Trials

CapTem Plus Radioembolization for NET Liver Metastases

CapTemY90
Start date: November 2021
Phase: Phase 2
Study type: Interventional

Grade 2 neuroendocrine tumors have an intermediate rate of progression following embolotherapy of liver metastases. The combination of capecitabine and temozolomide has been shown to be an active regimen in this disease. Both drugs are radiosensitizers, and in a safety and feasibility study were combined with yttrium-90 radioembolization with acceptable additive toxicities and better than expected response and duration of disease control. This study expands use of this regimen in a Phase 2 investigation to confirm efficacy of the integrated chemoradiation technique.

NCT ID: NCT04464122 Recruiting - Clinical trials for Neuroendocrine Tumors

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

REBORN
Start date: September 14, 2020
Phase:
Study type: Observational

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

NCT ID: NCT04339036 Recruiting - Clinical trials for Neuroendocrine Tumors

CapTemY90 for Grade 2 NET Liver Metastases

CapTemY90
Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.